Logo

GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19

Share this

GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19

Shots:

  • The EUA submission is based on an interim analysis of the P-III COMET-ICE study assessing VIR-7831 vs PBO for the early treatment of COVID-19 in 583 adults at high risk of hospitalization
  • The study demonstrated an 85% reduction in hospitalization. Due to evidence of profound efficacy- IDMC recommended stopping the trial for further enrollment
  • Preclinical data of VIR-7831 suggested that the mAB maintains its activity against emerging variants. Additionally- the companies will continue discussions with the EMA and other global regulators to make VIR-7831 available to patients with COVID-19 asap

­ Ref: GSK | Image: GSK

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions